Novel approaches to enhance the specificity and safety of engineered T cells Journal Article
| Authors: | Fedorov, V. D.; Sadelain, M.; Kloss, C. C. |
| Article Title: | Novel approaches to enhance the specificity and safety of engineered T cells |
| Abstract: | T-cell therapies using engineered T cells show great promise for cancer immunotherapy, as illustrated by the CD19 paradigm. Much of the excitement about this approach, and second-generation CARs in particular, is due to the dramatic clinical results recently reported by a few centers, especially in acute lymphoblastic leukemia, and the applicability of this approach, in principle, to a wide range of cancers. Extending the use of CAR therapies to cancers other than B-cell malignancies will require selective tumor targeting with minimal or acceptable "on-target, off-tumor" effects. The identification of new CAR target antigens is thus one of the next big challenges to address. Recognizing the paucity of currently available tumor-specific targets, we have developed broadly applicable approaches to enhance the tumor selectivity and safety of engineered T cells. Here, we review 2 promising concepts. One is to improve tumor targeting based on combinatorial antigen recognition. The other uses receptors that provide antigen-specific inhibition, which we named iCARs, to divert T cells from the normal tissues one wants to protect. Copyright © 2014 Lippincott Williams & Wilkins. |
| Keywords: | cancer immunotherapy; cd19; car therapies; t-cell therapies |
| Journal Title: | The Cancer Journal |
| Volume: | 20 |
| Issue: | 2 |
| ISSN: | 1528-9117 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2014-03-01 |
| Start Page: | 160 |
| End Page: | 165 |
| Language: | English |
| DOI: | 10.1097/ppo.0000000000000040 |
| PROVIDER: | scopus |
| PUBMED: | 24667964 |
| DOI/URL: | |
| Notes: | Export Date: 1 May 2014 -- CODEN: CAJOC -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work